The PI3Kα inhibitor alpelisib has demonstrated significant clinical benefit when combined with endocrine therapy in patients with HR-positive/HER2-negative advanced breast cancer harboring PIK3CA mutations (28). Here, ERBB2 is linked to breast carcinoma.